… Moreover, a systematic assessment of the interaction between CsA and the OATP substrate
pravastatin has been performed in rats, revealing that this interaction appears to be long-…

… that various observed clinical drug–drug interactions (DDIs) … Of note, DDIs involving the
inhibition of hepatic OATP1B1/3 (… at a low substrate concentration relative to the substrate …

… clinically relevant substrates and/or multiple substrates could … OATPs) 1B1 and 1B3 are
the major hepatic uptake transporters involved in the distribution and disposition of many drugs…

… Drug-drug interactions (DDIs) involving drug-metabolizing enzymes and membrane transporters
can lead to alteration in substrate drug (victim) … f t for OATP substrates was assessed by …

… Our objective was to evaluate potential drug-drug interactions of cilofexor as a victim and
as … (CYP3A substrate), atorvastatin (mixed OATP/CYP3A substrate), dabigatran etexilate (P-gp …

… OATP isoforms such as OATP1B1 and OATP1B3, aliskiren, celiprolol, and pemetrexed are
selective for OATP2B1 (5). As OATP2B1 substrates … which to conduct drug interaction studies (…

… of substrate drug pharmacokinetics and thereby sites of clinical drug–drug interactions (DDIs…
, evaluation of transport and inhibition of these two OATPs is standard in contemporary drug …

… To enable the identification of OATP substrates during the discovery phase, cell lines
expressing OATP1B1 or OATP1B3 can be used and the uptake CLint from these systems can be …

… for the identified in vivo OATP1B1 substrates and/ … gathered on the interaction with OATP1B1
is transferred into the … the OATP1B1 substrate pemafibrate, indicating OATP1B1 inhibition (…

… , labeled substrates and the investigated … drug interactions. The modulation of the ATP-dependent
vesicular uptake of a specific ABCB1 probe substrate directly reveals drug interactions …